Immunomediated Diseases and Innovative Therapies

Overview

The Immunomediated Diseases and Innovative Therapies is an heterogeneous area composed by both translational and clinical research groups which cover fields such as immunology, respiratory and systemic diseases, pharmacology, molecular diagnosis, heart repair, reumatology and advanced therapies. Its main strength derives precisely from this heterogeneity and the complementarity of the scientific interests and expertise of the different groups, many of which are currently joining efforts and synergizing in a variety of collaborative research projects.

Publications

214

total

1,338.943

impact factor

6.257

average impact factor

Group Leader: Jaume Alijotas Reig

team

zoom

download

Our team has continued working hard on autoimmune diseases, autoinflammatory disorders and newly-described disease such as IgG4-RD. The relationship of different autoantibody profiles with certain clinical subsets in myositis and systemic sclerosis has been fully analysed. The link between myositis/cancer and myositis related to biological cancer treatment is also being researched. The role played by the so-called “atypical” aPL in poor obstetric outcomes has also been studied, showing promising clinical results that could modify the current classification criteria for (OAPS). Evidence exists of the major role played by certain paternal molecules and immune cells. Thus, seminal molecules have to interact with immature dendritic/cells-Tregs. We are now analysing through proteomics, which types of protein act as sensitisers for NK cells and Tregs. We are analysing different molecular biomarkers and their capacity to predict flares, particularly renal flares, in patients with SLE. Gene-wide genetic and molecular signatures in patients with systemic necrotising vasculitis have been studied in blood samples of a European cohort. Determination of the extra-glandular involvement risk and the development of primary Sjögren syndrome by studying lymphoid populations and cytokines in blood and tissue samples have been successful. Finally, to seek biomarkers of clinical activity in patients with rheumatoid arthritis, extensive genomic methylation biomarkers have been studied.

62

total

435^.360

impact factor

7^.022

average impact factor

SELECTED ARTICLES

HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome.
Belizna C, Pregnolato F, Alijotas-Reig J, Abad S, Amital H, Amoura Z, Andreoli L, Andres E, Aouba A, Apras Bilgen S, Arnaud L, Bienvenu B, Bitsadze V, Blanco P, Blank M, Borghi MO, Caligaro A, Candrea E, Canti V, Chiche L, Chretien JM, Cohen Tervaert JW, Damian L, Delross T, Dernis E, Devreese K, Djokovic A, Esteve-Valverde E, Favaro M, Fassot C, Ferrer-Oliveras R, Godon A, Hamidou M, Hasan M, Henrion D, Imbert B, Jeandel PY, Jeannin P, Jego P, Jourde-Chiche N, Khizroeva J, Lambotte O, Landron C, Latino JO, Lazaro E, de Leeuw K, Le Gallou T, Kiliç L, Limper M, Loufrani L, Lubin R, Magy-Bertrand N, Mahe G, Makatsariya A, Martin T, Muchardt C, Nagy G, Omarjee L, Van Paasen P, Pernod G, Perrinet F, Pïres Rosa G, Pistorius MA, Ruffatti A, Said F, Saulnier P, Sene D, Sentilhes L, Shovman O, Sibilia J, Sinescu C, Stanisavljevic N, Stojanovich L, Tam LS, Tincani A, Tollis F, Udry S, Ungeheuer MN, Versini M, Cervera R, Meroni PL.
Autoimmun Rev. 2018 Dec;17(12):1153-1168. doi: 10.1016/j.autrev.2018.05.012.
Epub 2018 Oct 12. Review.
PMID: 30316994
IF: 8.745
Subclinical cardiovascular disease and Systemic Sclerosis: A comparison between risk charts, quantification of coronary calcium and carotid ultrasonography.
Sanz Pérez I, Martínez Valle F, Guillén-Del-Castillo A, Roque Pérez A, Cuéllar Calàbria H, Pizzi MN, Fernández Codina A, Callejas-Moraga E, Orozco Gálvez O, Fonollosa Pla V, Simeón Aznar CP.
Autoimmun Rev. 2018 Sep;17(9):900-905. doi: 10.1016/j.autrev.2018.03.015.
Epub 2018 Jul 11.
IF: 8.745
Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, Koné-Paut I, Lachmann HJ, Ozen S, Simon A, Zeft A, Calvo Penades I, Moutschen M, Quartier P, Kasapcopur O, Shcherbina A, Hofer M, Hashkes PJ, Van der Hilst J, Hara R, Bujan-Rivas S, Constantin T, Gul A, Livneh A, Brogan P, Cattalini M, Obici L, Lheritier K, Speziale A, Junge G.
N Engl J Med. 2018 May 17;378(20):1908-1919. doi: 10.1056/NEJMoa1706314.
PMID: 29768139
IF: 79.258
Classification and management of adult inflammatory myopathies.
Selva-O’Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, Milisenda JC, Grau-Junyent JM, Mammen AL.
Lancet Neurol. 2018 Sep;17(9):816-828. doi: 10.1016/S1474-4422(18)30254-0. Review.
PMID:30129477
IF: 27.138
Treatment and outcomes in patients with IgG4-related disease using the IgG4 responder index.
Fernández-Codina A, Pinilla B, Pinal-Fernández I, López C, Fraile-Rodríguez G, Fonseca-Aizpuru E, Carballo I, Brito-Zerón P, Feijóo-Massó C, López-Dupla M, Cid MC, Martínez-Valle F; Spanish Registry of IgG4 Related Disease (REERIGG4) investigators; Autoimmune Diseases Group (GEAS); Spanish Internal Medicine Society (SEMI).
Joint Bone Spine. 2018 Dec;85(6):721-726. doi: 10.1016/j.jbspin.2018.01.014. Epub 2018 Feb 13.
PMID: 29452298
IF: 3.304

View all publications

Immunomediated Diseases and Innovative Therapies

Overview

Publications

Group Leader: Jaume Alijotas Reig

Research Areas